CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients

被引:28
|
作者
Mohammadzadeh, Adel [1 ]
Rad, Isa Abdi [2 ]
Ahmadi-Salmasi, Babak [3 ]
机构
[1] Urmia Univ Med Sci, Dept Immunol & Genet, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Dept Genet, Orumiyeh, Iran
[3] Urmia Univ Med Sci, Dept Neurol, Imam Khomeini Hosp, Orumiyeh, Iran
关键词
CTLA-4; PD-1; TIM-3; Multiple sclerosis; T-CELL-ACTIVATION; MULTIPLE-SCLEROSIS; ASSOCIATION; MECHANISMS; GALECTIN-9; INFECTION; PROMOTES; DISEASE;
D O I
10.1016/j.jneuroim.2018.08.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS), is an autoimmune disorder of central nervous system (CNS) characterized by inflammation and demyelination. Self-tolerance impairment is considered to be induced by a combination of inherited susceptibility and environmental agents. In this work, we demonstrate that a reduction in the comparative expression of well-known inhibitory receptors (i.e., CTLA-4, PD-1, and TIM-3) is importantly linked with MS patients compared to healthy controls. The relative expression of interested genes was performed on peripheral blood mononuclear cells (PBMCs), by using quantitative real time-PCR (qRT-PCR). Our data high-lighted the role of inhibitory receptors in the maintenance of immune homeostasis in autoimmune disease.
引用
收藏
页码:105 / 108
页数:4
相关论文
共 50 条
  • [21] PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii
    Splitt, Samantha D.
    Souza, Scott P.
    Valentine, Kristen M.
    Castellanos, Brayan E.
    Curd, Andrew B.
    Hoyer, Katrina K.
    Jensen, Kirk D. C.
    INFECTION AND IMMUNITY, 2018, 86 (09)
  • [22] Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis
    Nakayama, Chieri
    Tanoue, Kiyonori
    Idichi, Tetsuya
    Shimomura, Hiroki
    Kita, Yoshiaki
    Hozaka, Yuto
    Shinden, Yoshiaki
    Matsushita, Daisuke
    Nakajo, Akihiro
    Arigami, Takaaki
    Mataki, Yuko
    Kurahara, Hiroshi
    Ohtsuka, Takao
    ANTICANCER RESEARCH, 2022, 42 (07) : 3373 - 3380
  • [23] Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma
    Landwehr, Laura-Sophie
    Altieri, Barbara
    Sbiera, Iuliu
    Remde, Hanna
    Kircher, Stefan
    Olabe, Julie
    Sbiera, Silviu
    Kroiss, Matthias
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (09) : 2325 - 2334
  • [24] Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
    Bruss, Christina
    Kellner, Kerstin
    Albert, Veruschka
    Hutchinson, James A.
    Seitz, Stephan
    Ortmann, Olaf
    Brockhoff, Gero
    Wege, Anja K.
    CANCERS, 2023, 15 (09)
  • [25] FoxP3, PD-1 and CTLA-4 are decreased significantly after a tenofovir therapy in patients with chronic hepatitis B
    Cho, Hyosun
    Kang, Hyojeung
    Kim, Ji Y.
    Kim, Hee Y.
    Kim, Chang W.
    FUTURE VIROLOGY, 2020, 15 (04) : 235 - 246
  • [26] Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
    Assal, Amer
    Kaner, Justin
    Pendurti, Gopichand
    Zang, Xingxing
    IMMUNOTHERAPY, 2015, 7 (11) : 1169 - 1186
  • [27] Polymorphisms of the Costimulatory Genes CTLA-4, CD28, PD-1, and ICOS and Outcome of Kidney Transplants in Iranian Patients
    Niknam, Ahmad
    Karimi, Mohammad Hossein
    Geramizadeh, Bita
    Roozbeh, Jamshid
    Yaghobi, Ramin
    Salehipour, Mehdi
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2017, 15 (03) : 295 - 305
  • [28] Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes
    Kamal, Amany M.
    Wasfey, Eman F.
    Elghamry, Wesam R.
    Sabry, Omar M.
    Elghobary, Hany A.
    Radwan, Sara M.
    CLINICAL BIOCHEMISTRY, 2021, 96 : 13 - 18
  • [29] Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
    Liu, Yu
    Yu, Yinyan
    Yang, Suguang
    Zeng, Bin
    Zhang, Zhuohan
    Jiao, Guohui
    Zhang, Yuan
    Cai, Limin
    Yang, Rongcun
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (05) : 687 - 697
  • [30] At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    Intlekofer, Andrew M.
    Thompson, Craig B.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (01) : 25 - 39